Clinical Trial Update: Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Nivolumab for patients with surgically resectable Stage IIB-IIC melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED